The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.00

Today's change-0.02 -0.33%
Updated January 18 2:25 PM -5GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.00

Today's change-0.02 -0.33%
Updated January 18 2:25 PM -5GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc crosses below 20-day moving average

Keryx Biopharmaceuticals Inc is lower today, dropping (U.S.)$0.02 or 0.33% to (U.S.)$6.00 and crossing below its 20-day moving average. Shares have lost 6.25% for the last five days, but have gained 82.37% over the last 52 weeks. This security has outperformed the S&P 500 by 61.71% during the last year.

Key company metrics

  • Open(U.S.) $6.03
  • Previous close(U.S.) $6.02
  • High(U.S.) $6.12
  • Low(U.S.) $5.99
  • Bid / Ask(U.S.) $6.00 / (U.S.) $6.01
  • YTD % change+2.39%
  • Volume485,620
  • Average volume (10-day)1,805,086
  • Average volume (1-month)1,413,785
  • Average volume (3-month)1,519,841
  • 52-week range(U.S.) $2.80 to (U.S.) $7.80
  • Beta4.99
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.56
Updated January 18 2:25 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-584.76%

Although this company's net profit margin is negative, it is above the industry average and implies that Keryx Biopharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.26%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue6976
Total other revenue--------
Total revenue6976
Gross profit-13454
Total cost of revenue19622
Total operating expense48333031
Selling / general / administrative21202122
Research & development9788
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-42-24-23-25
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-42-45-41-38
Income after tax-42-45-41-38
Income tax, total0000
Net income-42-45-41-38
Total adjustments to net income--------
Net income before extra. items-42-45-41-38
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-42-45-41-38
Inc. avail. to common incl. extra. items-42-45-41-38
Diluted net income-42-45-41-38
Dilution adjustment00--0
Diluted weighted average shares106106106105
Diluted EPS excluding extraordinary itemsvalue per share-0.39-0.42-0.39-0.36
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.39-0.42-0.39-0.36